citral has been researched along with Carcinoma, Hepatocellular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balaraman, G; Krishnan, P; Mari, A; Salam, S; Subramaniam, N; Sundaram, J; Thiruvengadam, D | 1 |
| HANNO, A; ODA, K; OSATO, S | 1 |
2 other study(ies) available for citral and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Citral inhibits N-nitrosodiethylamine-induced hepatocellular carcinoma via modulation of antioxidants and xenobiotic-metabolizing enzymes.
Topics: Acyclic Monoterpenes; alpha-Fetoproteins; Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Diethylnitrosamine; Humans; Liver Function Tests; Liver Neoplasms, Experimental; Male; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar | 2020 |
Experimental chemotherapy of cancer in rat with citral-combinations.
Topics: Acyclic Monoterpenes; Aldehydes; Animals; Carcinoma, Hepatocellular; Liver Neoplasms; Liver Neoplasms, Experimental; Monoterpenes; Neoplasms; Neoplasms, Experimental; Rats | 1953 |